JMP Securities Downgrades Enanta Pharma To Market Perform

Analysts at JMP Securities downgraded Enanta Pharmaceuticals ENTA from “market outperform” to “market perform” and removed the price target of $50. Enanta Pharma shares have surged 145.97% over the past 52 weeks, while the S&P 500 index has gained 21.67% in the same period. Enanta Pharma's shares gained 1.23% to close at $42.75 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesAnalyst RatingsJMP Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!